nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

01.09.2006 | REVIEW

Evidence for beneficial effects of antidepressants on suicidality in depressive patients

A systematic review

verfasst von: Prof. Hans-Jürgen Möller

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

The role of antidepressants in suicide prevention is a major public health question, given the high prevalence of both depression and depression-related suicidality. Therefore all means available should be utilised to clarify the influence of antidepressants on suicidality. This paper gives a comprehensive overview of the positive effects of antidepressants on suicidality. In the first section, principal methodological issues related to suicidology in general as well as to clinical and epidemiological studies that investigate the influence of antidepressants on suicidality are discussed. In the second section, the results of controlled clinical studies on the efficacy of antidepressants in suicidality are presented. The third section reports on the results of other types of studies, especially epidemiological studies. Altogether, there seems to be reasonable evidence from different research approaches that antidepressants are able to reduce suicidal ideation and also suicidal behaviour in depressive patients. While the evidence for the beneficial effect on suicidal ideation comes from randomised control group studies, some of which used a placebo arm, the evidence for the prophylactic effect on suicidal behaviour, especially suicide, was primarily obtained from well-designed epidemiological studies.

Bradvik L (2002) The occurrence of suicide in severe depression related to the months of the year and the days of the week. Eur Arch Psychiatry Clin Neurosci 252:28–32PubMed

Bradvik L, Berglund M (2000) Suidical ideation in severe depression. Eur Arch Psychiatry Clin Neurosci 250:139–143PubMedCrossRef

Bradvik L, Berglund M (2004) Suicide in severe depression related to treatment: depressive characteristics and rate of antidepressant overdose. Eur Arch Psychiatry Clin Neurosci 255:245–250PubMedCrossRef

Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2005) The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 62:165–172PubMedCrossRef

Isometsa ET, Henriksson MM, Aro HM, Heikkinen ME, Kuoppasalmi KI, Lonnqvist JK (1994) Suicide in major depression. Am J Psychiatry 151:530–536

Moller HJ (2003) Suicide, suicidality and suicide prevention in affective disorders. Acta Psychiatr Scand 108(Suppl. 418):73–80CrossRef

Baldwin D, Bullock T, Montgomery D, Montgomery S (1991) 5-HT reuptake inhibitors, tricyclic antidepressants and suicidal behaviour. Int Clin Psychopharmacol 6(Suppl. 3):49–55PubMedCrossRef

Isacsson G (2000) Suicide prevention–a medical breakthrough? Acta Psychiatr Scand 102:113–117PubMedCrossRef

Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 330:396PubMedCrossRef

10.

Möller HJ (1992) Antidepressants – do they decrease or increase suicidality? Pharmacopsychiatry 25:249–253PubMed

11.

Teicher MH, Glod CA, Cole JO (1993) Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf 8:186–212PubMed

12.

Grunebaum MF, Ellis SP, Li S, Oquendo MA, Mann JJ (2004) Antidepressants and suicide risk in the United States, 1985–1999. J Clin Psychiatry 65:1456–1462PubMedCrossRef

13.

Möller HJ (2006) Is there evidence for negative effects of antidepressants on suicidality in depressive patients? Eur Arch Psychiatry Clin Neurosci In Press

14.

Kurz A, Möller HJ, Baindl G, Burk F, Torhorst A, Wachtler C, Lauter H (1987) Classification of parasuicide by cluster analysis. Types of suicidal behaviour, therapeutic and prognostic implications. Br J Psychiatry 150:520–525PubMedCrossRef

15.

Kurz A, Möller HJ, Torhorst A, Lauter H (1988) Validation of six risk scales for suicide attempters. In: Möller HJ, Schmidtke A, Welz R (eds) Current issues of suicidology. Springer, Berlin, Heidelberg, New York, pp 174–178

16.

Lejoyeux M, Leon E, Rouillon F (1994) Prevalence and risk factors of suicide and attempted suicide. Encephale 20:495–503PubMed

17.

Möller HJ (1990) Suicide risk and treatment problems in patients who have attempted suicide. In: Lester D (eds) Current concepts of suicide. Charles Press, Philadelphia, pp 168–181

18.

Brown GK, Beck AT, Steer RA, Grisham JR (2000) Risk factors for suicide in psychiatric outpatients: a 20-year prospective study. J Consult Clin Psychol 68:371–377PubMedCrossRef

19.

Moscicki EK (1999) Epidemiology of suicide. In: Jacobs D (eds) The Harvard Medical School guide to suicide assessment and intervention. Jossey-Bass, San Francisco, pp 40–51

20.

ACNP (1993) Suicidal behavior and psychotropic medication. Accepted as a consensus statement by the ACNP Council, March 2, 1992. Neuropsychopharmacology 8:177–183

21.

Montgomery S, Cronholm B, Asberg M, Montgomery DB (1978) Differential effects on suicidal ideation of mianserin, maprotiline and amitriptyline. Br J Clin Pharmacol 5 (Suppl. 1):77S–80SPubMed

22.

Asberg M, Nordström P (1988) Biological correlates of suicidal behaviour. In: Möller HJ, Schmidtke A, Welz R (eds) Current issues of suicidology. Springer, Berlin, Heidelberg, New York, pp 221–241

23.

Traskman L, Asberg M, Bertilsson L, Sjostrand L (1981) Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry 38:631–636PubMed

24.

Rujescu D, Giegling I, Sato T, Möller HJ (2001) A polymorphism in the promoter of the serotonin transporter gene is not associated with suicidal behavior. Psychiatric Genet 11:169–172CrossRef

25.

Rujescu D, Giegling I, Sato T, Hartmann AM, Moller HJ (2003) Genetic variations in tryptophan hydroxylase in suicidal behavior: analysis and meta-analysis. Biol Psychiatry 54:465–473CrossRef

26.

Rujescu D, Giegling I, Sato T, Moller HJ (2003) Lack of association between serotonin 5-HT1B receptor gene polymorphism and suicidal behavior. Am J Med Genet 116B:69–71CrossRef

27.

Montgomery SA, McAuley R, Rani SJ, Roy D, Montgomery DB (1981) A double blind comparison of zimelidine and amitriptyline in endogenous depression. Acta Psychiatr Scand Suppl 290:314–327PubMed

28.

de Wilde J, Mertens C, Overo KF, Petersen HE (1985) Citalopram versus mianserin. A controlled, double-blind trial in depressed patients. Acta Psychiatr Scand 72:89–96PubMed

29.

Spitzer RL, Endicott J, Robins E (1978) Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 35:773–782PubMed

30.

Amin MM, Anath JV, Coleman BS, Darcourt G, Farkas T, Goldstein BJ, Lapierre YD, Paykel ES, Wakelin JS (1984) Fluvoxamine antidepressant effects confirmed in a placebo-controlled international study. Clin Neuropharmacol 7(Suppl. 1):580–581

31.

Wakelin JS (1988) The role of serotonin in depression and suicide: do serotonin reuptake inhibitors provide a key? In: Mendlewitcz JH, van Praag M (eds) Advances in biological psychiatry. Karger, Basel, pp 70–80

32.

Muijen M, Roy D, Silverstone T, Mehmet A, Christie M (1988) A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatr Scand 78:384–390PubMed

33.

Möller HJ, Steinmeyer EM (1994) Are serotonergic reuptake inhibitors more potent in reducing suicidality? An empirical study on paroxetine. Eur Neuropsychopharmacol 4:55–59PubMedCrossRef

34.

Beasley CM Jr., Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH Jr., Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN (1991) Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 303:685–692PubMedCrossRef

35.

Montgomery SA (1992) The advantages of paroxetine in different subgroups of depression. Int Clin Psychopharmacol 6(Suppl. 4):91–100PubMed

36.

Lopez-Ibor JJ (1993) Reduced suicidality with paroxetine. Eur Psychiatry 8(Suppl. 1):17s–19s

37.

Pedersen AG (2005) Escitalopram and suicidality in adult depression and anxiety. Int Clin Psychopharmacol 20:139–143PubMedCrossRef

38.

Khan A, Warner HA, Brown WA (2000) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57:311–317PubMedCrossRef

39.

Khan A, Khan SR, Leventhal RM, Brown WA (2001) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 4:113–118PubMedCrossRef

40.

Khan A, Khan S, Kolts R, Brown WA (2003) Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 160:790–792PubMedCrossRef

41.

Storosum JG, van Zwieten BJ, van den BW, Gersons BP, Broekmans AW (2001) Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry 158:1271–1275PubMedCrossRef

42.

Gunnell D, Saperia J, Ashby D (2005) Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 330:385PubMedCrossRef

43.

Carlsten A, Waern M, Ekedahl A, Ranstam J (2001) Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf 10:525–530PubMedCrossRef

44.

Rihmer Z (2001) Can better recognition and treatment of depression reduce suicide rates? A brief review. Eur Psychiatry 16:406–409PubMedCrossRef

45.

Rihmer Z, Appleby L, Rihmer A, Belso N (2000) Decreasing suicide in Hungary. Br J Psychiatry 177:84PubMedCrossRef

46.

Rihmer Z, Rutz W, Pihlgren H, Pestality P (1998) Decreasing tendency of seasonality in suicide may indicate lowering rate of depressive suicides in the population. Psychiatry Res 81:233–240PubMedCrossRef

47.

Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P (2003) Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. BMJ 326:1008PubMedCrossRef

48.

Olfson M, Shaffer D, Marcus SC, Greenberg T (2003) Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 60:978–982PubMedCrossRef

49.

FDA Public Health Advisory (2004) Suicidality in children and adolescents being treated with antidepressant medications. www. fda. gov/cder/drug/antidepressants/SSRIPHA200410

50.

Kelly CB, Ansari T, Rafferty T, Stevenson M (2003) Antidepressant prescribing and suicide rate in Northern Ireland. Eur Psychiatry 18:325–328PubMedCrossRef

51.

Barbui C, Campomori A, D’Avanzo B, Negri E, Garattini S (1999) Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates. Soc Psychiatry Psychiatr Epidemiol 34:152–156PubMedCrossRef

52.

Helgason T, Tomasson H, Zoega T (2004) Antidepressants and public health in Iceland. Time series analysis of national data. Br J Psychiatry 184:157–162PubMedCrossRef

53.

Rihmer Z (2004) Decreasing national suicide rates–fact or fiction? World J Biol Psychiatry 5:55–56PubMedCrossRef

54.

Van Praag HM (2003) A stubborn behaviour: the failure of antidepressants to reduce suicide rates. World J Biol Psychiatry 4:184–191PubMedCrossRef

54a.

Rihmer Z, Belso N, Kalmar S (2001) Antidepressants and suicide prevention in Hungery. Acta Psychiatr Scand 103:238–239PubMedCrossRef

55.

Isacsson G, Bergman U, Rich CL (1996) Epidemiological data suggest antidepressants reduce suicide risk among depressives. J Affect Disord 41:1–8PubMedCrossRef

56.

Isacsson G, Boethius G, Bergman U (1992) Low level of antidepressant prescription for people who later commit suicide: 15 years of experience from a population-based drug database in Sweden. Acta Psychiatr Scand 85:444–448PubMed

57.

Isacsson G, Holmgren P, Druid H, Bergman U (1997) The utilization of antidepressants – a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992–1994. Acta Psychiatr Scand 96:94–100PubMed

58.

Isometsa E, Henriksson M, Heikkinen M, Aro H, Lonnqvist J (1994) Suicide and the use of antidepressants. Drug treatment of depression is inadequate. BMJ 308:915

59.

Oquendo MA, Malone KM, Ellis SP, Sackeim HA, Mann JJ (1999) Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. Am J Psychiatry 156:190–194PubMed

60.

Angst J, Gamma A, Gastpar M, Lepine JP, Mendlewicz J, Tylee A (2002) Gender differences in depression. Epidemiological findings from the European DEPRES I and II studies. Eur Arch Psychiatry Clin Neurosci 252:201–209CrossRef

61.

Lepine JP, Gastpar M, Mendlewicz J, Tylee A (1997) Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12:19–29PubMed

62.

Tylee A, Gastpar M, Lepine JP, Mendlewicz J (1999) DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 14:139–151

63.

Tylee A, Gastpar M, Lepine JP, Mendlewicz J (1999) Identification of depressed patient types in the community and their treatment needs: findings from the DEPRES II (Depression Research in European Society II) survey. DEPRES Steering Committee. Int Clin Psychopharmacol 14:153–165

64.

Cheng AT (1995) Mental illness and suicide. A case–control study in east Taiwan. Arch Gen Psychiatry 52:594–603PubMed

65.

Isacsson G, Bergman U, Rich CL (1994) Antidepressants, depression and suicide: an analysis of the San Diego study. J Affect Disord 32:277–286CrossRef

66.

Isacsson G, Holmgren P, Wasserman D, Bergman U (1994) Use of antidepressants among people committing suicide in Sweden. BMJ 308:506–509

67.

Rich CL, Isacsson G (1997) Suicide and antidepressants in south Alabama: evidence for improved treatment of depression. J Affect Disord 45:135–142PubMedCrossRef

68.

Isacsson G, Wasserman D, Bergman U (1995) Self-poisonings with antidepressants and other psychotropics in an urban area of Sweden. Ann Clin Psychiatry 7:113–118PubMedCrossRef

69.

Kurz A, Möller HJ, Burk F, Torhorst A, Wachtler C, Lauter H (1985) Determination of treatment disposal for parasuicide patients in a German university hospital. Soc Psychiatry 20:145–151PubMedCrossRef

70.

Wasserman D, Persson ML (1993) Suicide. Lancet 342:745PubMedCrossRef

71.

Priest RG (1994) Improving the management and knowledge of depression. Br J Psychiatry 164:285–287PubMedCrossRef

72.

Mann JJ, Apter A, Bertolote J, Beautrais A, Currier D, Haas A, Hegerl U, Lonnqvist J, Malone K, Marusic A, et al. (2005) Suicide prevention strategies: a systematic review. JAMA 294:2064–2074PubMedCrossRef

73.

Rutz W, von Knorring L, Walinder J (1992) Long-term effects of an educational program for general practitioners given by the Swedish Committee for the Prevention and Treatment of Depression. Acta Psychiatr Scand 85:83–88PubMed

74.

Paykel ES, Tylee A, Wright A, Priest RG, Rix S, Hart D (1997) The Defeat Depression Campaign: psychiatry in the public arena. Am J Psychiatry 154:59–65PubMed

75.

Paykel ES (2001) Impact of public and general practice education in depression: evaluation of the defeat depression campaign. Psychiatria Fennica 32(Suppl. 2):51–61

76.

Rix S, Paykel ES, Lelliott P, Tylee A, Freeling P, Gask L, Hart D (1999) Impact of a national campaign on GP education: an evaluation of the Defeat Depression Campaign. Br J Gen Pract 49:99–102PubMed

77.

Paykel ES, Hart D, Priest RG (1998) Changes in public attitudes to depression during the Defeat Depression Campaign. Br J Psychiatry 173:519–522PubMed

78.

Althaus D, Niklewski G, Pfeiffer-Gerschel T, Schmidtke A, Hegerl U (2005) Vom “Nürnberger Bündnis gegen Depression” zur “European Alliance against Depression”. Modelle zur Optimierung der Versorgung depressiver Patienten. Nervenheilkunde 24:402–407

79.

Hegerl U, Althaus D, Stefanek J (2003) Public attitudes towards treatment of depression: effects of an information campaign. Pharmacopsychiatry 36:288–291PubMedCrossRef

80.

Henkel V, Mergl R, Kohnen R, Maier W, Moller HJ, Hegerl U (2003) Identifying depression in primary care: a comparison of different methods in a prospective cohort study. BMJ 326:200–201PubMedCrossRef

81.

Angst F, Stassen HH, Clayton PJ, Angst J (2002) Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord 68:167–181CrossRef

82.

Moller HJ, Grunze H, Broich K (2006) Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. Eur Arch Psychiatry Clin Neurosci 256:1–16PubMedCrossRef

83.

Yerevanian BI, Koek RJ, Feusner JD, Hwang S, Mintz J (2004) Antidepressants and suicidal behaviour in unipolar depression. Acta Psychiatr Scand 110:452–458PubMedCrossRef

84.

Cipriani A, Pretty H, Hawton K, Geddes JR (2005) Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 162:1805–1819PubMedCrossRef

85.

Coppen A, Standish-Barry H, Bailey J, Houston G, Silcocks P, Hermon C (1991) Does lithium reduce the mortality of recurrent mood disorders? J Affect Disord 23:1–7PubMedCrossRef

86.

Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003) Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290:1467–1473PubMedCrossRef

87.

Müller-Oerlinghausen B (1989) Pharmakotherapie pathologischen aggressiven und autoaggressiven Verhaltens. In: Pöldinger W, Wagner W (eds) Aggression, Selbstaggression, Familie und Gesellschaft. Springer, Berlin, Heidelberg, New York, pp 121–134

88.

Tondo L, Hennen J, Baldessarini RJ (2001) Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 104:163–172PubMedCrossRef

89.

Schrauzer GN, Shrestha KP (1990) Lithium in drinking water and the incidences of crimes, suicides, and arrests related to drug addictions. Biol Trace Elem Res 25:105–113PubMed

Titel: Evidence for beneficial effects of antidepressants on suicidality in depressive patients
A systematic review
verfasst von: Prof. Hans-Jürgen Möller
Publikationsdatum: 01.09.2006
Verlag: Steinkopff-Verlag
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 6/2006
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-006-0650-x

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2006

Midbrain dopamine D2/3 receptor binding in schizophrenia

The quality of life of the mentally ill living in residential facilities

Risperidone augmentation of clozapine

Cognitive predictors of skill acquisition on social problem solving in patients with schizophrenia